HLA-DR clone CR3/43

Working With CRT

Licensing Opportunities

Small Molecules

Biological Therapeutics

Enabling Technology

Antibody Catalogue

Privileged Access Section

CRT's Development Pipeline

Commercialisation Routes

Anti-HLA-DR Antibody Profile

Antigen:	HLA-DR (MHC class II)
Relevance:	HLAs are highly polymorphic proteins that are involved in the presentation of antigens to the T-cell receptor. There are two classes of HLA antigens, class I (HLA-A, HLA-B and HLA-C) and class II (HLA-D). These antibodies can be used for HLA typing
Clone:	CR3/43
Subclass:	IgG1
Applications:	Western blot, Immunohistochemistry (frozen and paraffin sections), FACS
Immunogen:	Tonsil cells
Reactivity:	Human
Species raised in:	Mouse
Fusion partner:	NS-1
Recommended growth conditions:	RPMI 1640 + 10% FCS + penicillin (100U/ml) + streptomycin (100mg/l) + glutamine (2mM) + HAT
References:	Gatter KC, Abdulaziz Z, Beverley P, Corvalan JRF, Ford C, Lane EB, Mota M, Nash JRG, Pulford K, Stein H, Taylor-Papadimitriou J, Woodhouse C, Mason DY (1982) Use of monoclonal antibodies for the histopathological diagnosis of human malignancy. J Clin Path 35:1253-1267 Gatter KC, Mason DY (1982) The use of monoclonal antibodies for histopathologic diagnosis of human malignancy. Semin Oncol 9:517-525 Erber WN, Falini B, Ghosh AK, Moir DJ, Mason DY (1983) Immuno-alkaline phosphatase labelling of haematological samples with monoclonal antibodies. In Feldmann G (ed) Proc 2nd Int Symp Immunoenzymatic Techniques, Elsevier, North Holland, p 29-40 Appendix. Table of workshop monoclonal antibodies and a synopsis of their principal characteristics (1984) In Steel CM (ed) Disease markers. Special Issue. Human MHC Class II Antigens: Genetics, Structure and Function. John Wiley & Sons Ltd., Sussex 2:363-369
Notes:	Please note this cell line has not been weaned out of HAT. Ultroser G can be used at 1% if the cells are not growing well

For further information about antibodies from CRT or to discuss sales or licensing options, please contact us at reagents@cancertechnology.com

Click here to view Notes and Disclaimer information

[back]